Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Salivary 8-hydroxy-2'-deoxyguanosine levels in patients with oral cancer: a systematic review and meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      8-Hydroxy-2'-Deoxyguanosine*/metabolism ; Mouth Neoplasms*/metabolism ; Saliva*/metabolism ; Saliva*/chemistry ; Oxidative Stress*; Humans ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/analysis
    • Abstract:
      Background: DNA is an important target for oxidative attack and its modification may increase the risk of mutagenesis. The aim of this study was to evaluate and compare salivary levels of the oxidative stress biomarker 8-hydroxy-2'-deoxyguanosine (8-OHdG) in patients with oral cancer (OC) compared to the control group by a comprehensive search of the available literature.
      Methods: The present systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and was registered in Open Science Framework (OSF): https://doi.org/10.17605/OSF.IO/X3YMR. Four electronic databases were used to identify studies for this systematic review: PubMed, Scopus, ScienceDirect, and Web of Science from January 15, 2005, to April 15, 2021. The Joanna Briggs Institute (JBI) tool was used to assess article quality.
      Results: Of the 166 articles identified, 130 articles were excluded on the basis of title and abstract screening (duplicates, reviews, etc.). Thirty-six articles were evaluated at full text and 7 articles met the inclusion criteria. Of these, only 5 studies had compatible data for quantitative analysis. An increase in salivary 8-OHdG levels was found in patients with OC compared to healthy subjects, but without statistical significance. 8-OHdG: SMD = 2,72 (95%CI= -0.25-5.70); *p = 0.07.
      Conclusions: This systematic review and meta-analysis suggests a clear trend of increased 8-OHdG levels in saliva of OC patients compared to the control group. However, further studies are required to clarify and understand the altered levels of this oxidative stress marker.
      (© 2024. The Author(s).)
    • References:
      Oral Oncol. 2020 Aug;107:104799. (PMID: 32446214)
      Curr Pharm Des. 2018;24(40):4771-4778. (PMID: 30767733)
      BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
      Biomed Pharmacother. 2019 Oct;118:109249. (PMID: 31351428)
      Biosensors (Basel). 2023 Jan 30;13(2):. (PMID: 36831972)
      J Dent Res. 2021 Nov;100(12):1313-1320. (PMID: 34036828)
      Acta Otolaryngol. 2023 Aug;143(8):709-713. (PMID: 37534452)
      Antioxidants (Basel). 2022 Jan 11;11(1):. (PMID: 35052649)
      Indian J Cancer. 2012 Jul-Sep;49(3):309-15. (PMID: 23238150)
      Int J Clin Exp Pathol. 2015 Sep 01;8(9):11884-94. (PMID: 26617944)
      Med Oral Patol Oral Cir Bucal. 2023 Nov 1;28(6):e530-e538. (PMID: 37471300)
      Dent Res J (Isfahan). 2013 May;10(3):287-95. (PMID: 24019794)
      Int J Mol Sci. 2018 Jun 08;19(6):. (PMID: 29890622)
      Acta Odontol Scand. 2019 Aug;77(6):408-418. (PMID: 30857448)
      Oral Oncol. 2021 Oct;121:105451. (PMID: 34329869)
      Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Nov;132(5):566-579. (PMID: 34518141)
      Int J Mol Sci. 2024 Feb 23;25(5):. (PMID: 38473882)
      Asian Pac J Cancer Prev. 2020 Aug 01;21(8):2325-2329. (PMID: 32856861)
      J Oral Pathol Med. 2012 Nov;41(10):736-40. (PMID: 22582895)
      F1000Res. 2020 Apr 2;9:229. (PMID: 32399208)
      J Cancer Res Ther. 2016 Apr-Jun;12(2):458-63. (PMID: 27461593)
      Expert Rev Proteomics. 2024 Apr;21(4):149-168. (PMID: 38626289)
      Oral Oncol. 2010 Jun;46(6):414-7. (PMID: 20400366)
      Healthcare (Basel). 2023 Jan 09;11(2):. (PMID: 36673562)
      Oral Oncol. 2009 Dec;45(12):1006-10. (PMID: 19828359)
      Clin Chim Acta. 2023 Aug 1;548:117503. (PMID: 37536520)
      SAGE Open Med. 2023 Sep 29;11:20503121231200757. (PMID: 37786898)
      J Cancer Res Ther. 2016 Apr-Jun;12(2):438-46. (PMID: 27461591)
      Biomark Med. 2023 Mar;17(6):337-347. (PMID: 37284735)
      Cancer. 2007 Jan 1;109(1):54-9. (PMID: 17099862)
      PLoS One. 2021 Mar 18;16(3):e0248167. (PMID: 33735248)
      Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):582-590. (PMID: 29673799)
      Jpn Dent Sci Rev. 2024 Dec;60:32-39. (PMID: 38204964)
      Clin Oral Investig. 2016 Mar;20(2):315-9. (PMID: 26077895)
      Adv Clin Chem. 2018;86:23-70. (PMID: 30144841)
      Anticancer Res. 2018 Sep;38(9):5211-5216. (PMID: 30194169)
      Head Neck Pathol. 2022 Mar;16(1):54-62. (PMID: 35312982)
      Hum Exp Toxicol. 2002 Feb;21(2):71-5. (PMID: 12102499)
    • Contributed Indexing:
      Keywords: 8-hydroxy-2′-deoxyguanosine; Biomarkers; Saliva; Squamous cell carcinoma of head and neck
    • Accession Number:
      88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
      0 (Biomarkers, Tumor)
    • Publication Date:
      Date Created: 20240806 Date Completed: 20240807 Latest Revision: 20240809
    • Publication Date:
      20240809
    • Accession Number:
      PMC11302223
    • Accession Number:
      10.1186/s12885-024-12746-0
    • Accession Number:
      39107689